tiprankstipranks
Ars Pharmaceuticals, Inc. (SPRY)
NASDAQ:SPRY
US Market
SPRY
ARS Pharmaceuticals
RESEARCH TOOLSreports
Want to see SPRY full AI Analyst Report?

ARS Pharmaceuticals (SPRY) Income Statement

567 Followers

ARS Pharmaceuticals Income Statement

Last quarter (Q4 2025), ARS Pharmaceuticals's total revenue was $28.09M, a decrease of -67.56% from the same quarter last year. In Q4, ARS Pharmaceuticals's net income was $-41.32M. See ARS Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Mar 22
Total Revenue
$ 84.28M$ 89.15M$ 30.00K$ 1.32M$ 5.51M
Gross Profit
$ 63.85M$ 68.59M$ 30.00K$ -15.80M$ 5.29M
Operating Expenses
$ 243.30M$ 71.67M$ 67.55M$ 19.71M$ 24.75M
Depreciation and Amortization
$ 1.37M$ 79.00K$ 73.00K$ 319.00K$ 213.00K
EBITDA
$ -178.08M$ -3.00M$ -67.45M$ -35.20M$ -19.24M
Operating Income
$ -179.45M$ -3.08M$ -67.52M$ -35.52M$ -19.45M
Other Income/Expenses
$ 8.07M$ 11.37M$ 13.15M$ 834.00K$ -789.00K
Pretax Income
$ -171.38M$ 8.29M$ -54.37M$ -34.68M$ -20.24M
Net Income
$ -171.30M$ 8.00M$ -54.37M$ -34.68M$ -20.24M
Per Share Metrics
Basic EPS
$ -1.74$ 0.08$ -0.57$ -0.87$ -0.70
Diluted EPS
$ -1.74$ 0.08$ -0.57$ -0.87$ -0.70
Weighted Average Shares Outstanding
 98.57M 96.94M 95.22M 39.96M 28.87M
Weighted Average Shares Outstanding (Diluted)
 98.57M 102.39M 95.22M 39.96M 28.87M
Currency in USD

ARS Pharmaceuticals Earnings and Revenue History